efficacy of odronextamab in r/r dlbcl & determining the optimal sequencing of immune therapies
Published 1 year ago • 218 plays • Length 1:51Download video MP4
Download video MP3
Similar videos
-
4:02
elm-2: promising safety and efficacy of odronextamab in r/r dlbcl
-
2:12
the optimal sequencing of therapies in waldenström’s macroglobulinemia
-
0:43
elm-2: qol and orr outcomes of odronextamab treatment for r/r fl
-
2:23
results from the phase ii elm-2 trial: odronextamab for r/r follicular lymphoma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
2:39
the role of bispecific antibodies in the treatment landscape for r/r dlbcl
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:54
the important role of bispecific antibodies in the future treatment of r/r dlbcl
-
2:41
cell avidity as a predictor of t-cell efficacy
-
2:57
lacutamab, an anti-kir3dl2 monoclonal antibody, in the treatment of r/r ptcl
-
1:00
phase ib trial of r-chop plus iberdomide or golcadomide in aggressive b-cell lymphoma
-
1:51
what do the elm-2 results tell us about the efficacy of odronextamab for r/r dlbcl?
-
2:41
an overview of the latest advances in hematology
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
1:03
the growing importance of single-cell rna sequencing in hematology
-
5:04
efficacy and safety of m-pola for r/r b-cell nhl
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
1:46
preclinical efficacy of the pkcβ inhibitor ms-553 in btki resistant cll
-
5:33
clinical utility of the homologous recombination deficiency score in aml & mds